Richard A. Miller - Publications, H-index & Citations

Richard A. Miller

university of texas health science center at san antonio

44H指数

201论文数

7.9K被引数

收录论文 43

发表时间

Hypothalamic sex-specific metabolic shift by canagliflozin during aging

GEROSCIENCE

IF5.4

2024-05-27

OAAI

Jayarathne, Hashan S. M.; Sullivan, Ryan; Stilgenbauer, Lukas; Debarba, Lucas K.; Kuchumov, Artur; Koshko, Lisa; Scofield, Sydney; Liu, Wanqing; Ginsburg, Brett C.; Miller, Richard A.; Sadagurski, Marianna

Selective ITK blockade induces antitumor responses and enhances efficacy to immune checkpoint inhibitors in preclinical models

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Hsu, Lih-Yun; Pawar, Rahul D.; Li, Dan; Ghosh, Poorva; Nguyen, Kevin; Williams, Carlene; Song, Yuqin; Ding, Ning; Verner, Erik; Miller, Richard A.

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2022-12-05

OAAI

Miller, Richard A.; Luke, Jason John; Hu, Shenshen; Mahabhashyam, Suresh; Jones, William B.; Marron, Thomas; Merchan, Jaime R.; Hughes, Brett G. M.; Willingham, Stephen B.

IMMUNOTHERAPY WITH B CELL ACTIVATING ANTIBODY CPI-006 IN PATIENTS (PTS) WITH MILD TO MODERATE COVID-19 STIMULATES ANTI-SARS-COV-2 ANTIBODY RESPONSE, MEMORY B CELLS AND MEMORY T EFFECTOR CELLS

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2020-12-10

OAAI

Criner, Gerard; Mobasher, Mehrdad; Hill, Craig; Hu, Shenshen; Mahabhashyam, Suresh; Brody, Joshua; Marron, Thomas; Willingham, Stephen; Miller, Richard

Targeting the A2AR in cancer; early lessons from the clinic

CURRENT OPINION IN PHARMACOLOGY

IF4.2

2020-08-01

OAAI

Willingham, Stephen B.; Hotson, Andrew N.; Miller, Richard A.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer 腺苷2A受体阻断作为治疗难治性肾细胞癌的免疫疗法

CANCER DISCOVERY

IF33.3

2020-01-09

236

OAAI

Fong, Lawrence; Hotson, Andrew; Powderly, John D.; Sznol, Mario; Heist, Rebecca S.; Choueiri, Toni K.; George, Saby; Hughes, Brett G. M.; Hellmann, Matthew D.; Shepard, Dale R.; Rini, Brian I.; Kummar, Shivaani; Weise, Amy M.; Riese, Matthew J.; Markman, Ben; Emens, Leisha A.; Mahadevan, Daruka; Luke, Jason J.; Laport, Ginna; Brody, Joshua D.; Hernandez-Aya, Leonel; Bonomi, Philip; Goldman, Jonathan W.; Berim, Lyudmyla; Renouf, Daniel J.; Goodwin, Rachel A.; Munneke, Brian; Ho, Po Y.; Hsieh, Jessica; McCaffery, Ian; Kwei, Long; Willingham, Stephen B.; Miller, Richard A.

BRONCHIECTASIS: A PROBABLE HARBINGER OF RHEUMATOID ARTHRITIS

CHEST

IF8.6

2019-10-01

PREAI

Meng, William; Al-khateeb, Anas; Miller, Richard; Patel, Rutwik; Kadri, Muqueet; Sharma, Hari; Bellary, Sharath

CPI-818: A selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) that inhibits T-cell receptor signaling, promotes Th1 skewing, and achieves objective tumor responses when administered to dogs with T cell lymphomas

CANCER RESEARCH

IF16.6

2019-07-01

PREAI

Janc, James W.; Hill, Craig M.; Ng, Patrick P.; Hoston, Andrew N.; Madriaga, Antonett; Dao-Pick, Trang P.; Yeung, Kitman S.; Hudson, Ryan; Beausoleil, Anne-Marie; Bradley, Erin; Verner, Erik; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.

Merkel cell polyomavirus is uncommon in New Zealand Merkel cell carcinomas

BRITISH JOURNAL OF DERMATOLOGY

IF9.6

2018-09-08

OAAI

Woodhouse, B.; Robb, T. J.; Hearn, J. I.; Houseman, P. S.; Hayward, G.; Miller, R.; Restall, A. P.; Findlay, M.; Lawrence, B.; Print, C. G.; Parker, K.; Blenkiron, C.

Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Willingham, Stephen; Hotson, Andrew; Ho, Po; Choy, Carmen; Walter, Kim; Yusko, Erik; Benzeno, Sharon; Laport, Ginna; Miller, Richard; McCaffery, Ian

A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T cell function

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Piccione, Emily C.; Mikesell, Glen; Daine-Matsuoka, Barbara; Walter, Kimberly; Miller, Richard; McCaffery, Ian

CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Emens, Leisha; Powderly, John; Fong, Lawrence; Brody, Joshua; Forde, Patrick; Hellmann, Matthew; Hughes, Brett; Kummar, Shivaani; Loi, Sherene; Luke, Jason; Mahadevan, Daruka; Markman, Benjamin; McCaffery, Ian; Miller, Richard; Laport, Ginna

Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Ho, Po; Hsieh, Meng-Yin; Hotson, Andrew; Miller, Richard; McCaffery, Ian; Willingham, Stephen

Phase 1/1b multicenter trial of the adenosine A2a receptor antagonist (A2aR) CPI-444 as single agent and in combination with atezolizumab (ATZ) in patients(Pts) with advanced cancers

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Patnaik, A.; Powderly, J.; Luke, J.; Miller, R.; Laport, G.

Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Willingham, S.; Ho, P.; Leone, R.; Choy, C.; Powell, J.; McCaffery, I.; Miller, R.

Not Your Father's, or Mother's, Rodent: Moving Beyond B6

NEURON

IF15

2016-09-01

OAAI

Miller, Richard A.

The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1

CANCER RESEARCH

IF16.6

2016-07-15

PREAI

Willingham, Stephen; Ho, Po; Leone, Robert; Piccione, Emily; Choy, Carmen; Hotson, Andrew; Buggy, Joseph; Powell, Jonathan; Miller, Richard

Evaluation of Resveratrol, Green Tea Extract, Curcumin, Oxaloacetic Acid, and Medium-Chain Triglyceride Oil on Life Span of Genetically Heterogeneous Mice

JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

IF3.8

2012-03-26

181

OAAI

Strong, Randy; Miller, Richard A.; Astle, Clinton M.; Baur, Joseph A.; de Cabo, Rafael; Fernandez, Elizabeth; Guo, Wen; Javors, Martin; Kirkland, James L.; Nelson, James F.; Sinclair, David A.; Teter, Bruce; Williams, David; Zaveri, Nurulain; Nadon, Nancy L.; Harrison, David E.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy 布鲁顿酪氨酸激酶抑制剂PCI-32765阻断b细胞活化，在自身免疫性疾病和b细胞恶性肿瘤模型中有效

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2010-07-06

1.5K

OAAI

Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.

Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression

MOLECULAR CANCER

IF33.9

2007-01-19

OAAI

Wang, Zhong; Lecane, Philip S.; Thiemann, Patricia; Fan, Qing; Cortez, Cecilia; Ma, Xuan; Tonev, Danielle; Miles, Dale; Naumovski, Louie; Miller, Richard A.; Magda, Darren; Cho, Dong-Gyu; Sessler, Jonathan L.; Pike, Brian L.; Yeligar, Samantha M.; Karaman, Mazen W.; Hacia, Joseph G.

研究方向